CV Viorica Ionut, MD PhD

                                                        Curriculum Vitae                                                       
A.  Personal Information:

Name

Viorica Ionut, MD PhD

Business Address

Department of Physiology and Biophysics

Keck School of Medicine ofUniversity of Southern California

1333 San Pablo St, MMR 626

Los Angeles, CA 90033

Business Phone

(323) 442-1937

Business Fax

(323) 442-2283

Place of Birth

Cluj-Napoca, Romania

E-Mail Address

ionut@usc.edu

Languages

English, French, Italian, Romanian

B.   Education:

Graduate School

University of Southern California, Los Angeles, CA, PhD (Physiology), 2005

Graduate School

Rutgers University, New Brunswick, NJ, MS (Nutrition), 2000

Medical School

University of Medicine and Pharmacy "Iuliu Hatieganu",Cluj-Napoca, Romania, MD,1993

Internship

University of Medicine and Pharmacy "Iuliu Hatieganu" University Hospital (Internal Medicine), Cluj-Napoca, Romania, 1993-1994

Residency

University of Medicine and Pharmacy "Iuliu Hatieganu" Department of Community Medicine and Family Practice (Preventive Medicine),Cluj-Napoca, Romania 1994-1998

Honors and Awards

Endocrine Society Scholars Award, 2007

 

Aventis Metabolism Scholar Award, American Federation for Medical Research Western Section, 2006

 

Aventis Metabolism Scholar Award, American Federation for Medical Research Western Section, 2005

 

Aventis Metabolism Scholar Award, American Federation for Medical Research Western Section, 2004

 

"Iuliu Moldovan" Award for Achievements in Basic Sciences, University of Medicine and Pharmacy Cluj-Napoca, Romania, 1995

C.  Professional Background:

Academic Appointments

 

Assistant Professor,  Dept of Physiology and Biophysics, Keck School of Medicine of USC, Los Angeles, CA, 2009-present.

Assistant Professor (tenure-track), Department of Community Medicine and Family Practice, University of Medicine and Pharmacy, Cluj-Napoca, 1994-1998

Other

 

Postdoctoral Research Associate, Dept of Physiology and Biophysics, Keck School of Medicine of USC, Los Angeles, CA, 2005-2008.

Postdoctoral Fellow, Dept of Physiology and Biophysics, Keck School of Medicine of USC, Los Angeles, CA, 2003-2005.

Research Assistant, Dept of Physiology and Biophysics, Keck School of Medicine of USC, Los Angeles, CA, 2000-2003.

Research Assistant, Rutgers University, Laboratory for Cancer Research, College of Pharmacy, Piscataway, NJ, 1999-2000.

Graduate Fellow, Rutgers University, Department of Nutritional Sciences, Cook College, New Brunswick, NJ, 1998-1999.

D.  Society Memberships:

Professional

            American Federation for Medical Research (AFMR) 2004- present

            North American Association for the Study of Obesity (NAASO) 2004-present

            Endocrine Society 2007-present

E.   Service:

University/Other Committees

Curriculum development committee, Department of Community Medicine and Family Practice, Cluj-Napoca, Romania, 1996-1998

      Symposia

Organizing committee member for "First International Conference on Primary Health Care", Cluj-Napoca, 27-31 May 1996.

F.   Research Activities:

Major Areas of Research Interest

Role of intestinal hormone GLP-1 and synthetic analogs in glucose homeostasis

Research in Progress

Role of GLP-1 and exenatide in increasing glucose disappearance independent of pancreatic hormones. Role of Exenatide on glucose homeostasis, insulin secretion and body fat.

Research Grants

1.

Exenatide effect on glucose homeostasis, insulin secretion and body habitus.

Amylin Inc, co-PI (P.I. Dr Richard N. Bergman)

 

2007- present

2.

Enhancement of Glucose Tolerance by Exenatide and GLP-1. Amylin Inc, co-PI (P.I. Dr Richard N. Bergman)

 

2005- present

3.

Role of Glucagon-like Peptide-1 (GLP-1) in glucose regulation.

American Diabetes Association Mentor-based fellowship (mentor: Dr. Richard N. Bergman, PhD)

 

2003- 2005

G.  Reviewer for

Expert Opinion on Investigational Drugs

H.  Bibliography:

Book chapters

 

  1. Bergman RN, Kim SP, Ellmerer M, Hucking K, Getty L, Kabir M, Ionut V, Richey J, Mittelman, Van Citters G and Ader M. Physiological basis of the metabolic syndrome. In: Progress in Obesity Research. Medeiro-Netos G, Halpern A and Bouchard C. (eds.), John Libbey Eurotext Ltd, 653-656, 2003

 

  1. Ionut V, Ionut C. Milk and dairy products. In: Foods and nutrition. Editura Medicala Universitara, Cluj-Napoca, 52-65 (in Romanian), 2001.

 

  1. Ionut V, Ionut C. Canned products and food poisoning. In: Foods and nutrition. Editura Medicala Universitara, Cluj-Napoca, 147-158 (in Romanian), 2001.

Books

 

  1. Ionut C, Laza V, Rusu I, Ionut V, Popa M. Practical applications in environmental health.  Editura Medicală Universitară " Iuliu Haţieganu", Cluj-Napoca, (in Romanian), 1998.

Peer Reviewed Articles

 

  1. Zheng D, Ionut V, Mooradian V, Stefanovski D, Bergman RN. Exenatide sensitizes insulin-mediated glucose uptake at skeletal muscle and liver. Diabetes. Feb; 58(2): 352-9, 2009.

 

  1. Ionut V, Zheng D, Stefanovski D, Bergman RN. Exenatide reduces peripheral glycemia independently of pancreatic hormones or gastric emptying in a canine animal model. Am J Physiol Endocrinol Metab. Aug; 295(2):E269-77, 2008.

 

  1. Hucking K, Hsu IR, Ionut V, Bergman RN. Deconvolution as a novel approach to analyze moment-to-moment free fatty acid release. Obesity Oct;15(10):2416-23, 2007.

 

  1. Ionut V, Liberty IF, Hucking K, Lottati M, Stefanovski D, Zheng D, Bergman RN. Exogenously imposed postprandial-like rises in systemic glucose and GLP-1 do not produce an incretin effect, suggesting an indirect mechanism of GLP-1 action. Am J Physiol Endocrinol Metab. Oct; 291(4):E779-85, 2006.

 

  1. Ionut V, Hucking K, Liberty IF and Bergman RN. Synergistic effect of portal glucose and GLP-1 to lower systemic glucose and stimulate counterregulatory hormones. Diabetologia. May; 48(5): 967-75, 2005.

 

  1. Ader M, Kim SP, Catalano KJ, Ionut V, Hucking K, Richey JM, Kabir M and Bergman RN. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes. 54(3):862-71, 2005.

 

  1. Ionut V, Kirkman E and Bergman RN. Investigation of the effect of acepromazine on intravenous glucose tolerance tests in dogs. American Journal of Veterinary Research Aug;65(8):1124-7, 2004.

 

  1. Sarbu D, Ionut C, Rusu I and Ionut V. Significance of anthropometric indices in evaluation of the nutritional status of young adults.  Clujul Medical, 71(2): 211-215, 1997. (in Romanian)

 

  1. Ionut C and Ionut V. Recent evaluations regarding the role of environmental factors in epidemiology and prevention of cardiovascular diseases.  Sibiul Medical, 4:15-22, 1995 (in Romanian).

 

Peer Reviewed Submitted

 

  1. Richey JM, Woolcott O, Stefanovski D, Harrison L, Zheng D, Lottati M , Hsu I, Kim SP, Kabir M,Catalano K, Chiu J, Ionut V, Kolka C, Mooradian V, Bergman RN. Rimonabant prevents additional accumulation of visceral and subcutaneous fat induced by high-fat diet in dogs. American Journal of Physiology January, 2009.

 

Peer Reviewed in Preparation

 

  1. Stefanovski D, Ionut V, Richey JM, Woolcott O, Lottati M, Zheng D, Harrison LN,  Kim SP, Hsu I, Bergman RN. Maintenance of the disposition index during high-fat diet induced insulin resistance in the canine model: evidence for the hyperbolic law of glucose tolerance

 

  1. Richey JM, Harrison LN, Woolcott O, Stefanovski D, Zheng D, Lottati M, Kim SP, Ionut V, Hsu I, Kolka C, Kabir M, Bergman RN. CB-1 receptor antagonism with rimonabant induces weight loss by transient reduction in food intake and preferential oxidation of stored fat.

 

  1. Kabir M, Stefanovski D, Hsu I, Woolcott O, Catalano K, Zheng D, Chiu J, Kim L, Harrison L, Lottati M, Ionut V, Bergman RN, Richey J. Rimonabant, the cannabanoid-1 receptor antagonist, prevents fat diet-induced accumulation of very large adipocytes in omental and subcutaneous fat depots in the canine model..

 

  1. Liberty IF, Ionut V, Kim SP, Stefanovski D, Lottati M, Bergman RN. Reduced glucocorticoid and glucose turnover represent the primary effects of HIV protease inhibitor Indinavir, accompanied by fat catabolism and fat deposition.  

 

5.      Kabir M, Kim SP, Ionut V, Dea MK and Bergman RN. Suppression of Glucose-6-phosphatase activity, measured in vivo, contributes to insulin suppression of endogenous glucose production.

 

Abstracts

 

  1. Harrison LN, Stefanovski D, Woolcott O, Lottati M, Zheng D, Ionut V, Kim SP, Hsu I, Kabir M, Catalano KJ, Chiu JD, Kolka C, Bergman RN, Richey JM. CB-1 receptor antagonist induces weight loss by transient reduction in food intake and preferential oxidation of stored fat. Obesity 16 [suppl 1], S265, 2008.

 

  1. Woolcott O, Kirkman E , Lottati M , Hsu I, Zheng D, Harrison L, Ionut V, Kim SP, Stefanovski D, Kolka C, Mooradian V, Kabir M, Chow R, Bergman RN, Richey J. CB-1 receptor antagonist rimonabant does not impair beta cell function. Obesity 16 [suppl 1], S28, 2008.

 

  1. Kabir M, Iyer MS, Stefanovski D, Hsu I, Woolcott O, Zheng D, Kim SP, Catalano K, Chiu J, Harrison L, Lottati M, Ionut V, Bergman RN, Richey J. Reduction of liver lipid accumulation by CB-1 antagonist is associated with an increase of adiponectin gene expression in the visceral fat depot of the fat-fed dog. Obesity 16 [suppl 1], S49, 2008.

 

  1. Kim SP, Woolcott O, Hsu I, Stefanovski D, Lottati M, Harrison L, Zheng D, Kolka C, Catalano K, Chiu J, Ionut V, Kabir M, Bergman RN, Richey JM. Evidence that CB-1 receptor antagonist improvement of insulin sensitivity precedes reduction of body fat. Obesity 16 [suppl 1], S270, 2008.

 

  1. Kabir M, Iyer MS, Stefanovski D, Hsu I, Woolcott O, Zheng D, Kim SP, Catalano K, Chiu J, Harrison L, Lottati M, Ionut V, Bergman RN, Richey J. Hepatoprotective effect of Rimonabant is associated with upregulation of adiponectin in the obese, insulin resistant dog. Diabetologia 51;[suppl 1]S293, 2008.

 

  1. Zheng D, Ionut V, Mooradian V, Stefanovski D, Bergman RN Exenatide sensitises insulin-mediated glucose uptake at liver and skeletal muscle, an effect amplified by hyperglycemia. Diabetologia 51;[suppl 1]S345, 2008.

 

  1. Ader M, Richey JM, Hucking K, Ionut V, Catalano KJ, Kim SP, Kabir M, Bergman RN. Increased caloric intake explains weight gain in some, but not all, antipsychotic therapy. Diabetologia 51;[suppl 1]S309, 2008.

 

  1. Woolcott O, Stefanovski D, Harrison L, Mooradian V, Zheng D, Lottati M, Dittman J, Kolka CM, Kim SP, Hsu I, Catalano K, Ionut V, Yae S, Bergman RN, Richey JM. Rimonabant reduces body weight and adiposity independent of changes in resting metabolic rate and food intake. Diabetologia 51;[suppl 1]S316, 2008.

 

  1. Zheng D, Ionut V, Mooradian V, Stefanovski D, Bergman RN Exenatide sensitizes insulin-mediated glucose uptake at skeletal muscle and liver. Diabetes 57 ( Suppl 1), A57, 2008.

 

  1. Richey JM, Woolcott O, Stefanovski D, Kim SP, Hsu I, Lottati M, Harrison L, Zheng D, Catalano K, Chiu J, Ionut V, Kabir M, Kolka C, Bergman RN. Maintenance of normal beta-cell function during treatment with Rimonabant. Diabetes 57 ( Suppl 1), A169, 2008.

 

  1. Stefanovski D, Richey JM, Kim SP, Zheng D, Woolcott O, Lottati M , Hsu I, Kolka C, Harrison L, Ionut V, Kabir M, Chiu J, Catalano K, Bergman RN. Rimonabant weight-loss independent effects on insulin action can be attributed to alterations in resting substrate utilization. Diabetes 57 (Suppl 1), A 402, 2008.

 

  1. Zheng D, Ionut V, Mooradian V, Stefanovski D, Bergman RN. Exenatide sensitizes insulin-mediated glucose uptake at skeletal muscle and liver. Journal of Investigative Medicine 56(1), 133, 2008.

 

  1. Ionut V, Zheng D, Stefanovski D, Bergman RN. Exenatide reduces glycaemia via a mechanism mediated by portal GLP-1 receptors but independent of islet hormones and intestinal motility. Diabetologia 50;[suppl 1]S245, 2007.

 

  1. Stefanovski D, Woolcott O, Lottati M , Zheng D, Harrison L, Ionut V, Kim SP, Hsu I, Chiu J, Catalano K, Kolka C, Richey JM, Bergman RN. Potential signals for beta cell compensation for insulin resistance. Diabetologia 50;[suppl 1]S27, 2007.

 

  1. Woolcott O, Richey JM, Harrison L, Stefanovski D, Zheng D, Lottati M , Kim SP, Catalano K, Chiu J, Hsu I, Ionut V, Kabir M, Bergman RN. Rimonabant prevents fat accumulation during a hypercaloric high-fat diet. Diabetologia 50;[suppl 1]S273, 2007.

 

  1. Richey JM, Woolcott O, Zheng D, Kim SP, Stefanovski D, Ionut V, Catalano K, Chiu J, Hsu I, Harrison L, Lottati M, Kabir M, Zuniga E, Kirkman E, Bergman RN. Cannabinoid receptor antagonist Rimonabant increases insulin sensitivity independent of weight loss. Diabetologia 50;[suppl 1]S273, 2007.

 

  1. Hsu I, Kabir M, Stefanovski D, Woolcott O, Zheng D, Catalano K, Chiu J, Kim L, Harrison L, Lottati M, Ionut V, Bergman RN, Richey J. Accumulation large adipocytes in omental and subcutaneous fat depots during development of obesity in dogs is preveted by Rimonabant. Diabetologia 50;[suppl 1]S274, 2007.

 

  1. Richey JM, Woolcott O, Kim SP, Stefanovski D, Ionut V, Catalano K, Chiu J, Hsu I, Harrison L,Lottati M, Zheng D, Kabir M, Zuniga E, Kirkman E, Kolka C, Bergman RN. Effect of CB-1 antagonist (Rimonabant) to increase insulin sensitivity, independent of weight loss. Diabetes 56 ( Suppl 1), 2007.

 

  1. Harrison L, Catalano K, Chiu J, Stefanovski D, Woolcott O, Lottati M , Zheng D, Ionut V, Kim SP, Hsu I, Kabir M, Kolka C, Zuniga E, Bergman RN,  Richey JM. Treatment with rimonabant improves insulin sensitivity in obese dogs without lowering elevated nocturnal free fatty acids. Diabetes 56 ( Suppl 1), 2007.

 

  1. Ionut V, Zheng D, Stefanovski D, Bergman RN. Novel Effect of Exenatide to Lower Glycemia Independent of Pancreas and Gut. Diabetes 56 (Suppl 1) A374, 2007.

 

  1. Zheng D, Catalano K, Chiu J, Harrison L, Hsu I, Ionut V, Kabir M, Kim SP, Lottati M, Stefanovski D, Woolcott O, Bergman RN,  Richey JM. Rimonabant, a selective CB 1 antagonist, increases plasma adiponectin independent of omental fat.. Diabetes 56 (Suppl 1), 2007.

 

  1. Stefanovski D, Woolcott O, Lottati M , Zheng D, Harrison L, Ionut V, Kim SP, Hsu I, Chiu J, Catalano K, Kolka C, Richey JM, Bergman RN. B-cell compensation for insulin resistance can occur absent any change in basal or 24-hour plasma glucose levels. Diabetes 56 (Suppl 1), 2007.

 

  1. Kabir M, Stefanovski D, Hsu I, Woolcott O, Catalano K, Zheng D, Chiu J, Kim L, Harrison L, Lottati M, Ionut V, Bergman RN, Richey J. Rimonabant, the cannabanoid-1 receptor antagonist, prevents fat diet-induced accumulation of very large adipocytes in omental and subcutaneous fat depots in the canine model. Diabetes 56 (Suppl 1), 2007.

 

  1. Stefanovski D, Woolcott O, Lottati M, Zheng D, Harrison LN, Ionut V, Kim SP, Hsu I, Bergman RN, Richey JM: Maintenance of glucose tolerance in diet-induced insulin resistant dogs. FASEB Journal 21:737.2, 2007.

 

  1. Harrison LN, Stefanovski D, Woolcott O, Lottati M, Zheng D, Ionut V, Kim SP, Hsu I, Kabir M, Catalano KJ, Chiu JD, Bergman RN, Richey JM. Cannabinoid receptor antagonist rimonabant prevents weight gain in dogs on a high fat diet. FASEB Journal 21:681.9, 2007.

 

  1. Ionut V, Stefanovski D, Lottati M, Zheng D, Kirkman E, Bergman RN. Portal GLP-1 produces an insulin-independent reduction in glycemia by increasing extrahepatic glucose disposal, without changing net hepatic glucose production. Diabetes 55 ( Suppl 1), A84, 2006.

 

  1. Kabir M, Stefanovski D, Hsu IR, Lottati M, Catalano KJ, Harrison N, Woolcott O, Chiu JD, Kim SP, Ionut V, Zheng D, Bergman RN, Richey JM. Fat deposition is greater in omental fat depot compared to subcutaneous depot in fat-fed dogs. Obesity 14 (9), A207, 2006.

 

  1. Ionut V, Stefanovski D, Lottati M, Kirkman E and Bergman RN. Portal GLP-1 produces an insulin-independent reduction in glycemia by increasing peripheral glucose disposal, without changing hepatic glucose balance. Journal of Investigative Medicine 54(1), S27, 2006.

 

  1. Ionut V, Liberty IF, Hucking K, Lottati M, Bergman RN. Direct action of glucose and GLP-1 on the pancreas might not be responsible for a significant portion of the incretin response during a mixed meal. Journal of Investigative Medicine 53(1), S106, 2005.

 

  1. Liberty IF, Ionut V, Kim SP, Stefanovski D, Lottati M, Bergman RN. Biphasic response to HIV protease inhibitors. Reduction in HPA axis followed by fat deposition, and switch to fat metabolism. Obesity Research 13, Suppl., 2005.

 

  1. Liberty IF, Ionut V, Kim SP, Stefanovski D, Lottati M, Bergman RN. Reduced glucose turnover is the primary effects of antiretroviral therapy, resulting in compensatory fat catabolism and visceral fat deposition. Diabetologia 48 Suppl 1 A212, P574, 2005.

 

  1. Ionut V, Liberty IF, Hucking K, Lottati M, Stefanovski D, Bergman RN. Exogenously imposed postprandial-like increases in systemic glucose and GLP-1 do not produce an incretin effect, suggesting a neural mechanism of GLP-1 action. Diabetes 54 Suppl 1 A362, 2005.

 

  1. Ader M, Catalano KJ, Ionut V, Kim SP, Hucking K, Richey JM, Kabir M and Bergman RN. Increased caloric intake explains weight gain in some, but not all, antipsychotic therapy. Diabetes 54 Suppl 1 A444, 2005.

 

  1. Hsu IR, Hucking K, Ionut V and Bergman RN. Mechanism of enhancement of oscillatory lipolysis during extended fasting. Diabetes  54Suppl 1 A356, 2005.

 

  1. Liberty IF, Ionut V, Kim SP, Ader M, Lottati M, Bergman RN. HIV-protease inhibitor treatment, a new canine experimental model of insulin resistance. Journal of Investigative Medicine 53(1), S106, 2005.

 

  1. Ader M, Catalano K, Ionut V, Kim S, Hucking K, Richey J, Kabir M, Bergman RN. Antipsychotic-induced weight gain: differential effects of olanzapine versus risperidone on caloric intake versus energy expenditure. Obesity Research 12, Suppl., 2004.

 

  1. Hsu I, Hucking K, Ionut V, Bergman R. Insulinopenia increases oscillatory lipolysis via upregulation of sympathetic nervous system. Obesity Research 12, Suppl., 2004.

 

  1. Ionut V, Hucking K, Liberty IF, Bergman RN. Portal GLP-1 reduces peripheral glycemia independent of insulin. Diabetes 53 Suppl 2 A340, 2004.

 

  1. Ader M, Kim SP, Hucking K, Catalano KJ, Ionut V, Richey JM, Kabir M and Bergman RN. Atypical antipsychotics prevent β-cell compensation for insulin resistance. Diabetes 53 Suppl 2, 2004.

 

  1. Hsu IR, Hucking K, Ionut V and Bergman RN. SNS driven oscillatory lipolysis is enhanced by insulinopenia. Diabetes  53 Suppl 2 A336, 2004.

 

  1. Ionut V, Hucking K and Bergman RN. Portal receptors are involved in the insulinotropic effect of GLP-1. Obesity Research 11, Suppl., 2003.

 

  1. Catalano K, Bergman RN, Kim S, Ionut V, Hucking K, Richey J, Kabir M, Ader M. Visceral fat depot with limited capacity determines insulin resistance in normal dogs. Obesity Research 11, Suppl., September 2003

 

  1. Hucking K, Ionut V, Moxness R and Bergman RN. Essential role of the CNS in augmentation of lipolysis after extended fasting. Diabetes 51, Suppl. 2, 2002.

 

  1. Kabir M, Ananthnarayan S, Ionut V, Kim SP, Van Citters GW, Dea MK and Bergman RN. Alterations in gene expression in the dog with visceral adiposity support portal free fatty acids flux as a causal factor for hepatic insulin resistance. Diabetes 51, Suppl. 2, 2002.

 

  1. Kabir M, Ananthnarayan S, Ionut V, Kim SP, Van Citters GW, Dea MK and Bergman RN. Depot-specific differences in LPL and HSL gene expression in adipose tissue may account for an elevation of gluconeogenic enzymes mRNA in fat fed dogs. Obesity Research 9, Suppl. 3, 2001.

 

Miscellany

 

Presentations

 

  1. Ionut V, Hucking K and Richard N. Bergman. Portal Glucagon-like peptide 1 (GLP-1) and portal glucose synergize to stimulate insulin secretion. Scientific proceedings of the American Federation for Medical Research Western Section Meeting, Carmel, CA, January 2004.

 

  1. Ionut V, Hucking K and Bergman RN. Measurements of active glucagon-like peptide-1 (GLP-1) portal - peripheral gradient in conscious dogs indicate that half of the released GLP-1 reaches the pancreas. Scientific proceedings of the American Federation for Medical Research Western Section Meeting, Carmel, CA January 2003.

 

 

Poster Sessions

  1. Ader M, Catalano KJ, Kim SP, Hucking K, Ionut V, Richey JM, Kabir M, Simpson G and Bergman RN. Differences in pancreatic b-cell compensation for insulin resistance between atypical antipsychotics:  results of a placebo-controlled study in normal dogs. Scientifc proceedings of the American College of Neuropsychopharmacology meeting, San Juan, Puerto Rico, December 2003.

 

  1. Ader M, Kim SP, Catalano KJ, Ionut V, Hucking K, Richey JM, Kabir M and Bergman RN. Marked increase in adiposity during olanzapine versus risperidone and placebo treatment in dogs. Scientific proceedings of the American Psychiatric Association Institute on Psychiatric Services meeting, Boston, MA,  Oct-Nov 2003.

 

  1. Ader M, Catalano KJ, Kim SP, Hucking K, Ionut V, Richey JM, Kabir M, Simpson G and Bergman RN. Differences in b-cell compensation for insulin resistance between atypical antipsychotics:  results of a placebo-controlled study in normal dogs. Scientific proceedings, European College of Neuropsychopharmacology meeting, Prague, Czech Republic, September 2003.

 

  1. Ader M, Catalano KJ, Ionut V, Kim SP, Hucking K, Richey JM, Kabir M and Bergman RN. Differential metabolic effects between atypical antipsychotics in normal dogs. Scientific proceedings of the International Diabetes Federation meeting, Paris, France, August 2003.

 

  1. Ionut V, Hucking K and Bergman RN. Portal hyperglycemia is important for eliciting an insulin response in the presence of GLP-1. Scientific proceedings, The Endocrine Society's 85th Annual Meeting, Philadelphia, PA, June 2003.

 

  1. Hucking K, Ionut V, Bergman RN. Deconvolution analysis as a novel approach to measure moment-to-moment free fatty acid (FFA) release. Scientific proceedings, American Diabetes Association annual meeting, New Orleans, LA, June 2003.

 

  1. Ader M, Catalano K, Ionut V, Kim S, Hucking K, Richey J, Kabir M and Bergman RN. Differential metabolic effects between atypic antipsychotics in normal dogs. Scientific proceedings, American Diabetes Association annual meeting, New Orleans, LA, June 2003.

 

  1. Richey J, Hucking K, Catalano K, Kim S, Ionut V, Kabir M, Bergman RN and Ader M. The Disposition Index is the major predictor of the glucose pattern during an OGTT in normal dogs. Scientific proceedings, American Diabetes Association annual meeting, New Orleans, LA, June 2003.

 

9.      Kabir M, Kim SP, Ionut V, Dea MK and Bergman RN. Suppression of Glucose-6-phosphatase activity measured in vivo, contributes to insulin suppression of endogenous glucose production. Scientific proceedings, American Diabetes Association annual meeting, Philadelphia, PA, June 2001. 

  1. Smith TJ, Ionut V, Yang GY and Yang CS. Inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung tumorigenesis by dietary olive oil. Scientific proceedings, 91th Annual meeting of the American Association for Cancer Research, San Francisco, CA, April 2000.

 

  1. Ionut V, Ionut C. Dietary habits of medical students. Scientific proceedings, "University of Medicine and Pharmacy Days";27,  Cluj-Napoca, Romania, 1997.

 

  1. Ionut C, Ionut V. Dosing from tissues as indicator of micronutrients bioavailability. Proceedings of the Symposium "Vitamins and biofactors", Nancy, France, 1996.

 

  1. Rusu I, Ionut V, Valeanu G. Comparative study of the physical development of schoolchildren from two areas with different levels of pollution. Proceedings of "Scientific session of Medical Center for Health Services and Management": 32, Cluj-Napoca, Romania. 1996.

 

  1. Ionut V, Ionut C. Comparative study of the physical development of medical students. Proceedings of "First International Conference on Primary Health Care":22, Cluj-Napoca, Romania, 1996.

 

  1. Ionut V,  Rusu I, Sarbu D, Ionut C, Bocu T, Kulcsar S, Micu V and Strugaru V. Aspects of the morphological and functional devlopment of young adults. Scientific proceedings of "University of Medicine and Pharmacy Days": 42, Cluj-Napoca, Romania, 1995.

 

  1. Sarbu D, Ionut C, Rusu I, Ionut V, Bocu T and Kulcsar S. Advantages of using skinfolds in determining the muscular mass in young adults and children. Scientific proceedings of "University of Medicine and Pharmacy Days": 43, Cluj-Napoca, Romania, 1995.

 


Copyright © 2009 Asociatia Medicala Romana
Concept and Web Design by WebCell.ro

Valid CSS!